Anika Therapeutics Profit Margin

The latest profit margin for ANIK is -1.89% as of June 2026. That compares with -66.01% in the prior-year period — up 97.1% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Anika Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANIK's profit margin moved from -66.01% to -1.89% — a 97.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Anika Therapeutics's valuation or profitability profile.

Against Healthcare companies, ANIK currently prints -1.89% for profit margin, while the sector average sits near 14.34%. That is roughly 113.1% below the sector mean. Large gaps often invite a closer look at Anika Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Anika Therapeutics converts resources into returns. At -1.89%, ANIK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -66.01% in the prior-year period — up 97.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ANIK's profit margin (-1.89%), review year-over-year change from -66.01%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.